These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 18163013)

  • 1. B-type natriuretic peptide as a marker of asymptomatic re-stenosis after coronary implantation of a paclitaxel-eluting stent.
    Lo Mauro R; Arcoleo F; Lo Giudice A; Picone A; Schirosa M; Raspanti G; Cillari E; Enia F
    J Cardiovasc Med (Hagerstown); 2007 Dec; 8(12):1020-3. PubMed ID: 18163013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of drug-eluting balloons in percutaneous treatment of bifurcation lesions: the DEBIUT (drug-eluting balloon in bifurcation Utrecht) registry.
    Fanggiday JC; Stella PR; Guyomi SH; Doevendans PA
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):629-35. PubMed ID: 18360855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stent strut fracture: seeing is believing.
    Carter AJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):619-20. PubMed ID: 18360854
    [No Abstract]   [Full Text] [Related]  

  • 4. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter).
    Rittger H; Waliszewski M; Brachmann J; Hohenforst-Schmidt W; Ohlow M; Brugger A; Thiele H; Birkemeyer R; Kurowski V; Schlundt C; Zimmermann S; Lonke S; von Cranach M; Markovic S; Daniel WG; Achenbach S; Wöhrle J
    JACC Cardiovasc Interv; 2015 Nov; 8(13):1695-700. PubMed ID: 26476609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial.
    Chevalier B; Di Mario C; Neumann FJ; Ribichini F; Urban P; Popma JJ; Fitzgerald PJ; Cutlip DE; Williams DO; Ormiston J; Grube E; Whitbourn R; Schwartz LB;
    JACC Cardiovasc Interv; 2008 Oct; 1(5):524-32. PubMed ID: 19463354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stent fracture, an incidental finding or a significant marker of clinical in-stent restenosis?
    Shaikh F; Maddikunta R; Djelmami-Hani M; Solis J; Allaqaband S; Bajwa T
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):614-8. PubMed ID: 18360853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study.
    Unverdorben M; Vallbracht C; Cremers B; Heuer H; Hengstenberg C; Maikowski C; Werner GS; Antoni D; Kleber FX; Bocksch W; Leschke M; Ackermann H; Boxberger M; Speck U; Degenhardt R; Scheller B
    EuroIntervention; 2015 Dec; 11(8):926-34. PubMed ID: 25169589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial.
    Kufner S; Cassese S; Valeskini M; Neumann FJ; Schulz-Schüpke S; Hoppmann P; Fusaro M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA;
    JACC Cardiovasc Interv; 2015 Jun; 8(7):877-84. PubMed ID: 26003022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of distal/bifurcation left main restenosis after drug eluting stents implantation: single center experience.
    Rigatelli G; Cardaioli P; Dell'Avvocata F; Giordan M; Vassilev D; Fraccaro C; Roncon L; Faggian G
    Cardiovasc Revasc Med; 2014 Mar; 15(2):76-9. PubMed ID: 24560299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and study design of the OISTER trial: optical coherence tomography evaluation of stent struts re-endothelialization in patients with non-ST-elevation acute coronary syndromes--a comparison of the intrEpide tRapidil eluting stent vs. taxus drug-eluting stent implantation.
    Iaccarino D; Politi L; Rossi R; Sgura F; Monopoli D; Modena MG; Sangiorgi GM
    J Cardiovasc Med (Hagerstown); 2010 Jul; 11(7):536-43. PubMed ID: 20090547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic implication of change in b-type natriuretic peptide (BNP) for prediction of subsequent target lesion revascularization following silorimus-eluting stent deployment.
    Hasumi E; Iwata H; Kohro T; Manabe I; Kinugawa K; Morisaki N; Ando J; Sawaki D; Takahashi M; Fujita H; Yamashita H; Ako J; Hirata Y; Komuro I; Nagai R
    Int J Cardiol; 2013 Sep; 168(2):1429-34. PubMed ID: 23302112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stenting for unprotected left main coronary artery stenosis: a further step.
    Cottin Y
    Arch Cardiovasc Dis; 2008 Jan; 101(1):7-8. PubMed ID: 18391865
    [No Abstract]   [Full Text] [Related]  

  • 15. The artisan approach for stenting bifurcation lesions.
    Colombo A; Latib A
    JACC Cardiovasc Interv; 2010 Jan; 3(1):66-7. PubMed ID: 20129571
    [No Abstract]   [Full Text] [Related]  

  • 16. Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial.
    Loh JP; Stella PR; Sangiorgi G; Silber S; Stahnke S; von Strandmann RP; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2014 Jan; 15(1):23-8. PubMed ID: 24444473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel predictor of restenosis and adverse cardiac events: asymmetric dimethylarginine.
    Ari H; Ari S; Erdoğan E; Tiryakioğlu O; Ustündağ Y; Huysal K; Koca V; Bozat T
    Heart Vessels; 2010 Jan; 25(1):19-26. PubMed ID: 20091394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The predictive value of inflammatory activity and markers of the adipo-insular axis on restenosis in patients with type 2 diabetes.
    Hage C; Grip L; Malmberg K; Rydén L; Wallander M; Saleh N
    Diab Vasc Dis Res; 2011 Apr; 8(2):143-9. PubMed ID: 21562066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of a polymer-free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-eluting stent (TAXUS) in real-world coronary artery lesions.
    Ruef J; Störger H; Schwarz F; Haase J
    Catheter Cardiovasc Interv; 2008 Feb; 71(3):333-9. PubMed ID: 18288747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stent fracture: an unusual cause of late restenosis after sirolimus-eluting stent placement.
    Mehrle A; Skelton T; Almonacid A
    Catheter Cardiovasc Interv; 2007 Jun; 69(7):988-91. PubMed ID: 17191207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.